The National Heart, Lung, and Blood Institute (NHLBI) awarded a $558,291 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of Colorado, doing business as the University of Colorado-Denver. The 4-year award, effective July 2024, will support research to investigate the role of the enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in cardiac fibrosis and heart failure. The project aims to test the hypothesis that inhibiting 15-PGDH can prevent and reverse the activation of cardiac fibroblasts, thereby mitigating pathological fibrotic remodeling of the heart. The research combines in vitro studies and in vivo animal models to elucidate the mechanisms by which 15-PGDH-mediated eicosanoid degradation contributes to cardiac fibrosis, with the goal of developing targeted therapies to address this unmet clinical need.
Generated 1/28/25, 9:28 AM